Literature DB >> 19322181

Thrombotic microangiopathy: what not to learn from a meta-analysis.

Marina Noris, Giuseppe Remuzzi.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19322181     DOI： 10.1038/nrneph.2009.28

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  6 in total

1.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

Authors:  Jessica Caprioli; Marina Noris; Simona Brioschi; Gaia Pianetti; Federica Castelletti; Paola Bettinaglio; Caterina Mele; Elena Bresin; Linda Cassis; Sara Gamba; Francesca Porrati; Sara Bucchioni; Giuseppe Monteferrante; Celia J Fang; M K Liszewski; David Kavanagh; John P Atkinson; Giuseppe Remuzzi
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

2.  Successful plasma therapy in hemolytic uremic syndrome with factor H deficiency.

Authors:  S Nathanson; V Frémeaux-Bacchi; G Deschênes
Journal:  Pediatr Nephrol       Date:  2001-07       Impact factor: 3.714

Review 3.  Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials.

Authors:  Mini Michael; Elizabeth J Elliott; Jonathan C Craig; Greta Ridley; Elisabeth M Hodson
Journal:  Am J Kidney Dis       Date:  2008-10-31       Impact factor: 8.860

4.  Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.

Authors:  Anne-Laure Sellier-Leclerc; Veronique Fremeaux-Bacchi; Marie-Agnès Dragon-Durey; Marie-Alice Macher; Patrick Niaudet; Geneviève Guest; Bernard Boudailliez; François Bouissou; Georges Deschenes; Sophie Gie; Michel Tsimaratos; Michel Fischbach; Denis Morin; Hubert Nivet; Corinne Alberti; Chantal Loirat
Journal:  J Am Soc Nephrol       Date:  2007-06-28       Impact factor: 10.121

5.  Thrombotic thrombocytopenic purpura: evidence that infusion rather than removal of plasma induces remission of the disease.

Authors:  P Ruggenenti; M Galbusera; R P Cornejo; P Bellavita; G Remuzzi
Journal:  Am J Kidney Dis       Date:  1993-03       Impact factor: 8.860

6.  Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation.

Authors:  Jean Claude Davin; Lisa Strain; Tim H J Goodship
Journal:  Pediatr Nephrol       Date:  2008-05-16       Impact factor: 3.714
  6 in total
  3 in total

1.  Dual RAS blockade-controversy resolved.

Authors:  Piero Ruggenenti; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2013-09-10       Impact factor: 28.314

Review 2.  Thrombotic microangiopathy and associated renal disorders.

Authors:  Thomas Barbour; Sally Johnson; Solomon Cohney; Peter Hughes
Journal:  Nephrol Dial Transplant       Date:  2012-07       Impact factor: 5.992

Review 3.  Deficiency of CFHR plasma proteins and autoantibody positive hemolytic uremic syndrome: treatment rationale, outcomes, and monitoring.

Authors:  Franca Iorember; Anjali Nayak
Journal:  Pediatr Nephrol       Date:  2020-06-12       Impact factor: 3.714
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.